RBC Capital raised the firm’s price target on Boston Scientific (BSX) to $130 from $125 and keeps an Outperform rating on the shares as part of a broader research note previewing 2026 for Medical Supplies & Devices. The firm anticipates a year of positive momentum as sector fundamentals are solidly intact driven by the aging demographics, growing global healthcare access, and differentiated innovation, the analyst tells investors in a research note. For the company, RBC believes it has a clear pathway to consistent double-digit EPS growth driven by top-tier organic revenue growth and strong operating margin expansion.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target lowered to $131 from $132 at Canaccord
- Boston Scientific’s WATCHMAN FLX Pro Registry: A New Frontier in Atrial Fibrillation Treatment
- 3 Best ETFs to Invest In, According to AI Analyst, 12/09/2025
- Boston Scientific’s Strong Growth Potential in EP Market Justifies Buy Rating
- Boston Scientific put volume heavy and directionally bearish